China based Adagene, Inc., an innovative antibody discovery and engineering company, has announced a multi-target platform evaluation with Celgene Corporation. Under the terms of the agreement, Adagene will use its Dynamic Precision Library, to discover antibodies against targets chosen by Celgene.  Additional details and financial terms of the agreement are not disclosed.

"Adagene's Dynamic Precision Library has continuously showcased its power to identify functional antibodies against difficult targets where traditional methods have failed," said Dr. Peter Luo, CEO of Adagene. "We look forward to partnering with Celgene to identify novel antibodies against challenging targets."

"The Dynamic Precision Library is designed for broad epitope coverage while keeping the developability of those candidates in mind," said Dr. Felix Du, Head of Technology Development at Adagene. "There are quality control checks throughout the process to ensure fidelity.  As a result, we can move very quickly to engineer therapeutic leads with tailor-made product profiles that directly translate into clinical candidates of value to our clients."